Pharmacokinetics of Methylphenidate Transdermal System (MTS): Results from a Laboratory Classroom Study
Authors:
- 1 August 2008
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 18 (4) , 355-364
Abstract
To evaluate the pharmacokinetic properties of the methylphenidate transdermal system (MTS) in pediatric patients diagnosed with ADHD (attention-deficit/hyperactivity disorder) in a laboratory school setting. A phase II, randomized, double-blind, placebo-controlled, laboratory classroom study was conducted with prior dose optimization. Children (aged 6-12 years) with ADHD were titrated over 5 weeks to an optimal clinical MTS dose (10, 15, 20, or 30 mg/9 h). Participants were randomized to 1 week of either MTS or corresponding placebo, followed by crossover to the alternate treatment. Laboratory school evaluations, including pharmacokinetic blood sampling, occurred at the end of each treatment. MTS delivered d- and l-MPH (methylphenidate) into the systemic circulation throughout the 9-hour wear time, and plasma concentrations declined rapidly after patch removal. Over the time-course of clinical effectiveness (2-12 h), mean plasma concentrations of d-MPH at the most frequently titrated doses (15 and 20 mg/9 h) ranged from 4.97 to 28.3 ng/mL. Systemic exposure increased approximately dose proportionately. Plasma concentrations of the l-MPH were approximately one-half to two-thirds those for d-MPH. Plasma concentrations of the much less active l-MPH were consistently lower than those of d-MPH. The clinical relevance of the MTS pharmacokinetic profile is discussed.Keywords
This publication has 27 references indexed in Scilit:
- Methylphenidate and its IsomersCNS Drugs, 2006
- Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity DisorderNeuropsychopharmacology, 2002
- Methylphenidate (OROS??Formulation)CNS Drugs, 2001
- Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity DisorderPediatrics, 2000
- Stimulant MedicationsJournal of the American Academy of Child & Adolescent Psychiatry, 1999
- Pharmacokinetics and Clinical Effectiveness of MethylphenidateClinical Pharmacokinetics, 1999
- Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial Reliability and Validity DataJournal of the American Academy of Child & Adolescent Psychiatry, 1997
- Medication Treatment Strategies in the MTA Study: Relevance to Clinicians and ResearchersJournal of the American Academy of Child & Adolescent Psychiatry, 1996
- Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorderAmerican Journal of Psychiatry, 1993
- THE BEHAVIOR OF CHILDREN RECEIVING BENZEDRINEAmerican Journal of Psychiatry, 1937